Johnson & Johnson (NYSE:JNJ) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 9.420-9.570 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.500. The company issued revenue guidance of $90.60 billion-$91.60 billion, compared to the consensus revenue estimate of $92.23 billion.
Shares of NYSE:JNJ traded up $2.60 during trading on Tuesday, reaching $167.81. The stock had a trading volume of 554,463 shares, compared to its average volume of 8,150,773. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. The business has a fifty day moving average price of $162.67 and a 200-day moving average price of $156.40. The stock has a market cap of $441.79 billion, a PE ratio of 25.98, a PEG ratio of 3.06 and a beta of 0.70. Johnson & Johnson has a 1-year low of $133.65 and a 1-year high of $173.65.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Monday, April 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.34 by $0.25. The firm had revenue of $22.30 billion for the quarter, compared to analyst estimates of $22 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.30 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current year.
A number of equities analysts have weighed in on JNJ shares. Credit Suisse Group boosted their price objective on Johnson & Johnson from $168.00 to $193.00 and gave the stock an outperform rating in a research note on Wednesday, January 27th. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $157.00 to $175.00 and gave the stock a neutral rating in a research note on Wednesday, January 27th. Cantor Fitzgerald boosted their price objective on Johnson & Johnson from $180.00 to $200.00 and gave the stock an overweight rating in a research note on Tuesday, January 26th. Cowen boosted their price objective on Johnson & Johnson from $170.00 to $195.00 and gave the stock an outperform rating in a research note on Wednesday, January 27th. Finally, Morgan Stanley upped their price target on Johnson & Johnson from $178.00 to $187.00 and gave the company an overweight rating in a research note on Wednesday, January 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. Johnson & Johnson presently has a consensus rating of Buy and an average target price of $182.45.
A hedge fund recently bought a new stake in Johnson & Johnson stock. OLD Mission Capital LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,432 shares of the company’s stock, valued at approximately $362,000. 67.25% of the stock is currently owned by hedge funds and other institutional investors.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: Net Margin
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.